{"id":"14a06fcf-b5ca-49e4-9788-429c0331d5c9","kind":"institutions","code":"UB-I7418","name":"Deep Track Capital","nameBasis":"original-brand","summary":"Deep Track Capital is a U.S. early-stage venture capital firm.","description":"Deep Track Capital is a U.S. early-stage venture capital firm.","country":null,"category":null,"originalName":"Deep Track Capital","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T20:00:14.111Z","englishUpdatedAt":"2026-10-16T01:39:37.635Z","reviewedAt":"2026-10-16T01:39:37.635Z","snapshotAt":"2026-10-16T01:37:59.763Z","sourceHash":"105ee39856c232d2c629cefd964939faec8c928054bdf7b307b5018c9b26d2f2","companyId":null,"foundedYear":null,"logoUrl":null,"originalText":"Deep Track Capital，美国早期风险投资机构。","sources":[],"related":[{"id":"22da73b7-c7eb-4a01-b246-146e4f248acc","kind":"news","code":"22da73b7-c7eb-4a01-b246-146e4f248acc","name":"Superluminal Medicines raises USD 60 million in Series B financing","nameBasis":"translated-title","summary":"On 2026-09-03, according to Xiniu Data, Superluminal Medicines completed Series B financing, raising USD 60 million. Investors were lead investor BVF Partners, RA Capital Management, Perceptive Advisors, NVIDIA and others. The company is a provider of U.S. AI generation drugs services.","description":"","country":null,"category":null,"originalName":"Superluminal Medicines完成B轮融资，融资金额6000万美元","eventDate":"2026-09-03T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-14T11:42:26.621Z","englishUpdatedAt":"2026-10-15T20:50:21.999Z","reviewedAt":"2026-10-15T20:50:21.999Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"e8e7b1b012c19476316906130fd4ae28ebac9db6102a8c78bc6bf24e9a1a83b0","companyId":"7c66c728-c0c9-4716-992b-f0a5fc8d890e","foundedYear":null,"logoUrl":null,"path":"/news/22da73b7-c7eb-4a01-b246-146e4f248acc"}],"path":"/institutions/deep-track-capital","canonical":"https://uniquebase.ai/institutions/deep-track-capital"}